scholarly article | Q13442814 |
P356 | DOI | 10.1056/NEJM199101173240303 |
P698 | PubMed publication ID | 1984192 |
P2093 | author name string | Canadian Hydroxychloroquine Study Group | |
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | systemic lupus erythematosus | Q1485 |
hydroxychloroquine | Q421094 | ||
P304 | page(s) | 150-154 | |
P577 | publication date | 1991-01-01 | |
P1433 | published in | The New England Journal of Medicine | Q582728 |
P1476 | title | A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus | |
P478 | volume | 324 |
Q37131283 | 2013 update: Hopkins lupus cohort |
Q89234856 | A complicated multisystem flare of systemic lupus erythematosus during pregnancy |
Q33777430 | A conceptual framework for clinical trials in SLE and other multisystem diseases |
Q41926759 | A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus |
Q41926859 | A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group |
Q92737146 | An audit of the use of hydroxychloroquine in rheumatology clinics |
Q47625953 | An overview of the treatment of childhood SLE. |
Q34226976 | Antimalarial therapy: a panacea for mild lupus? |
Q33529416 | Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. |
Q34604474 | Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit |
Q34297582 | Antimalarials--the 'real' advance in lupus |
Q34129797 | Antimalarials. |
Q93208741 | Applying the ethical principles of resource allocation to drugs in limited supply during a public health crisis |
Q41916954 | Association of Polymorphisms of Cytochrome P450 2D6 With Blood Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus |
Q36573884 | Association of discoid lupus erythematosus with clinical manifestations and damage accrual in a multiethnic lupus cohort |
Q91973791 | Autophagy in cancer: moving from understanding mechanism to improving therapy responses in patients |
Q30645037 | Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials |
Q51031046 | Biochemical characterization of ADP-ribose polymer metabolism in SLE. |
Q64236851 | CD72 is a Negative Regulator of B Cell Responses to Nuclear Lupus Self-antigens and Development of Systemic Lupus Erythematosus |
Q104559093 | COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease |
Q97526732 | Caspase1/11 signaling affects muscle regeneration and recovery following ischemia, and can be modulated by chloroquine |
Q49349531 | Causes and predictors of mortality in biopsy-proven lupus nephritis: the Sarawak experience |
Q58603726 | Characterisation of Patients with Systemic Lupus Erythematosus in Malta: A Population Based Cohort Cross-Sectional Study |
Q90939644 | Chloroquine Is Effective for Maintenance of Remission in Autoimmune Hepatitis: Controlled, Double-Blind, Randomized Trial |
Q41913969 | Chloroquine gestational use in systemic lupus erythematosus: assessing the risk of child ototoxicity by pure tone audiometry. |
Q41943173 | Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients |
Q41945144 | Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients |
Q41943280 | Chloroquine treatment reduces the number of cutaneous HLA-DR+ and CD1a+ cells in patients with systemic lupus erythematosus |
Q29615065 | Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors |
Q35686749 | Cigarette smoking and response to antimalarials in cutaneous lupus erythematosus patients: evolution of a dogma |
Q47133837 | Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey. |
Q26741266 | Current and emerging treatment options in the management of lupus |
Q41064137 | Cutaneous purpura of Sjögren syndrome successfully treated with hydroxychloroquine |
Q24243533 | Dehydroepiandrosterone for systemic lupus erythematosus |
Q24245412 | Dehydroepiandrosterone for systemic lupus erythematosus |
Q33422958 | Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus |
Q38776952 | Development and validation of a clinical HPLC method for the quantification of hydroxychloroquine and its metabolites in whole blood |
Q37453947 | Developments in the clinical understanding of lupus |
Q39449781 | Diffuse lymphadenopathy as the presenting manifestation of systemic lupus erythematosus |
Q46490126 | Discontinuation rate and factors predictive of the use of hydroxychloroquine in LUMINA, a multiethnic US cohort (LUMINA XL). |
Q36171764 | Disease activity assessment in SLE: do we have the right instruments? |
Q45107051 | Disease specific problems related to drug therapy in pregnancy |
Q36677040 | Drug exposure, pregnancy outcome and fetal and childhood development occurring in the offspring of mothers with systemic lupus erythematosus and other chronic autoimmune diseases |
Q49835073 | Dynamic patterns and predictors of hydroxychloroquine nonadherence among Medicaid beneficiaries with systemic lupus erythematosus |
Q41919066 | Early hydroxychloroquine macular toxicity |
Q43417859 | Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. |
Q31107094 | Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) |
Q50222848 | Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort |
Q41913718 | Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial |
Q36922219 | Elderly-onset systemic lupus erythematosus: prevalence, clinical course and treatment |
Q36634248 | Emerging drug therapies for systemic lupus erythematosus |
Q33957431 | Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology |
Q41917690 | Evidence of transplacental passage of hydroxychloroquine in humans |
Q41922310 | Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study |
Q92026856 | Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues |
Q36793954 | Experimental designs for small randomised clinical trials: an algorithm for choice |
Q41914711 | Factors Related to Blood Hydroxychloroquine Concentration in Patients With Systemic Lupus Erythematosus |
Q33731760 | Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. |
Q41919391 | Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. |
Q90157934 | Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy |
Q36240425 | Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence |
Q41915986 | Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis |
Q41930905 | Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study |
Q36906782 | Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients |
Q49383523 | Hydroxychloroquine desensitization, an effective method to overcome hypersensitivity-a multicenter experience |
Q38658480 | Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety |
Q95302006 | Hydroxychloroquine hitting the headlines-retinal considerations |
Q97646016 | Hydroxychloroquine in Dermatology and Beyond: Recent Update |
Q38029146 | Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects |
Q41927831 | Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). |
Q41336601 | Hydroxychloroquine inhibits CD154 expression in CD4+ T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling |
Q33411608 | Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies |
Q36246166 | Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus |
Q99726452 | Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence |
Q55507790 | Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. |
Q58608203 | Hydroxychloroquine retinopathy - implications of research advances for rheumatology care |
Q96431036 | Hydroxychloroquine shortage |
Q41942520 | Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus |
Q41944990 | Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis |
Q53798136 | Hydroxychloroquine-Induced Erythema Multiforme. |
Q26782822 | Hydroxychloroquine-related retinal toxicity |
Q41934841 | Hydroxychloroquine: a new therapeutic approach to the thrombotic manifestations of antiphospholipid syndrome |
Q46643929 | Hydroxychloroquine: the cornerstone of lupus therapy |
Q47396929 | Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome? |
Q38883883 | Immunomodulators in SLE: Clinical evidence and immunologic actions |
Q54365434 | Immunosuppressive treatment for pure membranous lupus nephropathy in a Hispanic population. |
Q64227620 | Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients: A systematic review and meta-analysis |
Q41917416 | Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study |
Q50493859 | Improved strategies for designing lupus trials with targeted therapies: learning from 65 years of experience. |
Q47743642 | Innate immune response gene expression profiles characterize primary antiphospholipid syndrome. |
Q33744320 | Interferon-alpha: a therapeutic target in systemic lupus erythematosus |
Q36302245 | Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis |
Q61831377 | Le lupus érythémateux disséminé de l'enfant |
Q99571380 | Leveraging Existing Strategies of Medication Stewardship to Preserve and Appropriately Use Critical Supplies |
Q34227000 | Local therapy for cutaneous and systemic lupus erythematosus: practical and theoretical considerations |
Q39789199 | Long-term Outcome of Lupus Nephritis Class II in Argentine Patients: An Open Retrospective Analysis |
Q39608521 | Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome |
Q36820979 | Lupus activity in pregnancy |
Q36373318 | Lupus in Baltimore: evidence-based 'clinical pearls' from the Hopkins Lupus Cohort |
Q38608138 | Lupus nephritis: an update |
Q40613454 | Lupus patients in an emergency unit. Causes of consultation, hospitalization and outcome. A cohort study. |
Q40599033 | Lupus therapy |
Q37121353 | Lupus: improving long-term prognosis |
Q40086624 | Lymphadenitis and systemic lupus erythematosus |
Q64084551 | Lysosomal pH Is Regulated in a Sex Dependent Manner in Immune Cells Expressing |
Q77091376 | Management of collagen vascular diseases in childhood |
Q44913899 | Managing lupus nephritis in pregnant women: comment on the article by Hahn et al. |
Q36386474 | Medication Nonadherence Is Associated With Increased Subsequent Acute Care Utilization Among Medicaid Beneficiaries With Systemic Lupus Erythematosus |
Q33777440 | Methodological issues of corticosteroid use in SLE clinical trials |
Q53920423 | Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. |
Q46076332 | Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients: a retrospective study |
Q89285609 | Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article |
Q38816742 | New Perspectives in Rheumatology: Avoiding Antimalarial Toxicity |
Q34007922 | New concepts in antimalarial use and mode of action in dermatology |
Q38026787 | New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. |
Q90412368 | New therapeutic strategies in systemic lupus erythematosus management |
Q38425824 | Optimizing the use of existing therapies in lupus. |
Q28660110 | Pediatric lupus nephritis: Management update |
Q40681350 | Pediatric rheumatic diseases. |
Q41444884 | Periodontal implications: mucocutaneous disorders |
Q36942997 | Pharmacokinetics and Bioequivalence Study of Hydroxychloroquine Sulfate Tablets in Chinese Healthy Volunteers by LC-MS/MS. |
Q38771936 | Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus |
Q33555419 | Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort |
Q33913777 | Practice and Educational Gaps in Lupus, Dermatomyositis, and Morphea |
Q38600390 | Predictive factors of flares in systemic lupus erythematosus patients: data from a multiethnic Latin American cohort. |
Q47100353 | Predictors of incident proteinuria among patients with SLE. |
Q37100267 | Pregnancy and autoimmune connective tissue diseases |
Q34417671 | Pregnancy and lupus nephritis |
Q77798505 | Pregnancy in SLE |
Q38794847 | Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population? |
Q41941085 | Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival |
Q48341665 | Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy. |
Q52316454 | Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. |
Q41917167 | Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort |
Q33455990 | Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort |
Q33945242 | Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United States |
Q41915954 | Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE |
Q35824537 | Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do? |
Q52889113 | Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. |
Q74554250 | Reactions and interactions of some commonly used systemic drugs in dermatology |
Q41582396 | Recognition and management of systemic lupus erythematosus |
Q38826018 | Remission and withdrawal of therapy in lupus nephritis. |
Q37768733 | Reporting of corticosteroid use in systemic disease trials: evidence from a systematic review of the potential impact on treatment effect |
Q35877606 | Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis |
Q51031044 | Respiratory function in systemic lupus erythematosus: relation with activity and severity. |
Q41931972 | Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI). |
Q35222834 | Review: Treatment of Cutaneous Lupus Erythematosus |
Q38295046 | Rituximab: an emerging treatment for recurrent diffuse alveolar hemorrhage in systemic lupus erythematosus |
Q98383294 | Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials |
Q41915008 | Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: A study of one hundred thirty‐three cases compared with a control group |
Q47253208 | Sample size considerations for superiority trials in systemic lupus erythematosus (SLE). |
Q36307429 | Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study |
Q31129756 | Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). |
Q36074980 | Specific systemic lupus erythematosus disease manifestations in the six months prior to conception are associated with similar disease manifestations during pregnancy |
Q38634472 | Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus |
Q41946634 | Synthetic antimalarials |
Q79878050 | Systemic Lupus Erythematosus Vasculitis: A Current Therapeutic Overview |
Q73730202 | Systemic lupus erythematosus |
Q84420574 | Systemic lupus erythematosus |
Q39053129 | Systemic lupus erythematosus diagnosis and management |
Q41933225 | Systemic lupus erythematosus flare-up manifesting as a cilioretinal artery occlusion |
Q41944292 | Systemic lupus erythematosus in children and adolescents |
Q34034374 | Systemic lupus erythematosus in the elderly. |
Q83623481 | Systemic lupus erythematosus in the elderly: antimalarials in disease remission |
Q53194239 | Systemic lupus erythematosus risk factors for coronary artery calcifications. |
Q40506580 | Systemic lupus erythematosus--disease management |
Q41920469 | Systemic lupus erythematosus-associated acute transverse myelitis: manifestations, treatments, outcomes, and prognostic factors in 20 patients |
Q41333508 | Systemic lupus erythematosus. Diagnosis and treatment |
Q35597979 | Systemic lupus erythematosus. How to manage, when to refer |
Q93193261 | Systemic lupus erythematosus: Diagnosis and clinical management |
Q36792304 | Systemic lupus erythematosus: current state of diagnosis and treatment |
Q38709337 | TSG-6 Downregulates IFN-Alpha and TNF-Alpha Expression by Suppressing IRF7 Phosphorylation in Human Plasmacytoid Dendritic Cells |
Q40951725 | The antiphospholipid syndrome and SLE: is there a clue in the link between complement and coagulation? |
Q41921799 | The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients |
Q37634514 | The case for Zostavax vaccination in systemic lupus erythematosus |
Q38540167 | The evolution of drug discovery in systemic lupus erythematosus |
Q36577380 | The management of pediatric systemic lupus erythematosus |
Q40188124 | The national incidence and clinical picture of SLE in children in Australia - a report from the Australian Paediatric Surveillance Unit |
Q38446538 | The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus |
Q48867556 | The randomized placebo-phase design for clinical trials |
Q37947108 | The role of antimalarial agents in the treatment of SLE and lupus nephritis |
Q38897055 | Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus |
Q34074960 | Therapy of systemic lupus erythematosus: new agents and new evidence |
Q36147794 | Thrombosis in systemic lupus erythematosus: a review article |
Q90048328 | Time to Lupus Low Disease Activity State in the Hopkins Lupus Cohort: Role of African American Ethnicity |
Q34932177 | Toll-like receptors as potential therapeutic targets for multiple diseases |
Q50726116 | Treatment Algorithms for Patients with Systemic Lupus Erythematosus: Comment on the Article by Muangchan et al. |
Q41207949 | Treatment Algorithms in Systemic Lupus Erythematosus |
Q28087628 | Treatment of Bullous Systemic Lupus Erythematosus |
Q41925126 | Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options? |
Q78814998 | Treatment of lupus nephritis |
Q35456519 | Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies |
Q38271125 | Treatment of severe lupus nephritis: the new horizon. |
Q74022703 | Treatment of systemic lupus erythematosus |
Q37974990 | Treatment of systemic lupus erythematosus: new advances in targeted therapy |
Q36840264 | Treatment of systemic lupus erythematosus: which options do we have for therapy regimens? |
Q33342024 | Treatment options for juvenile-onset systemic lupus erythematosus |
Q43962381 | Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus |
Q38764104 | What Causes Lupus Flares? |
Q38920435 | Why targeted therapies are necessary for systemic lupus erythematosus |
Q33410001 | Women, kidney disease, and pregnancy |
Q84600129 | [Antimalarials: an update in rheumatic diseases] |
Q78679215 | [Current therapy of lupus nephritis] |
Q78506325 | [Kidney, lupus and pregnancy] |
Q77114590 | [Lupus nephropathy: implications of a long course] |
Q81057481 | [Systemic lupus erythematosus and accelerated atheromatosis] |
Q89894663 | [Tapering and termination of immunosuppressive therapy : Systemic lupus erythematosus] |
Search more.